VICO Therapeutics
Business Services · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
J.h. Oortweg Bioscience Park Biopartner ...Phone Number
+31 712036800Website
www.vicotx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About VICO Therapeutics
Vico Therapeutics is a neurology genetic medicine company that pioneers RNA-based therapies targeting the root causes of rare genetic neurological diseases, specifically focusing on polyglutamine disorders like Huntington's disease and spinocerebellar ataxias. Their lead candidate, VO659, employs an innovative allele-preferential approach to reduce disease-causing mutations while preserving normal gene function. Committed to patient-centered care, Vico collaborates with patients, caregivers, and advocacy groups to drive meaningful change in the treatment landscape. By addressing the genetic source of these disorders, Vico Therapeutics aims to transform the lives of those affected by neurodegenerative diseases.Explore more
VICO Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is VICO Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at VICO Therapeutics
Check out if VICO Therapeutics is spiking on competitors!
Click to see if VICO Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once VICO Therapeutics has new funding data
Earning: See what the market has to say on VICO Therapeutics recently announced quarterly report
Check if VICO Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when VICO Therapeutics launches new products
VICO Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
VICO Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
VICO Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about VICO Therapeutics.
VICO Therapeutics financials insights
Gather financial insights about VICO Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series B
$70M
VICO Therapeutics Tech Stack
A closer look at the technologies used by VICO Therapeutics
See more technologies
Most Recent Scoops
Hiring Plans
VICO Therapeutics is hiring in Human Resources for the first time in 12 months.
Hiring Plans
Funding
Funding
Funding
New Hire
Executive Move
New Hire
Executive Move
VICO Therapeutics News & Media
Vico Therapeutics B.V. announced that it has received ?65.5 million in funding from a group ...
On June 24, 2024, Vico Therapeutics B.V. closed the transaction. On the same date, the company raised ?11.5 million in its second and final tranche, bringing total funding raised in the transaction...Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
Funding supports ongoing Phase 1/2a clinical trial evaluating VO659 in patients with spinocerebellar ataxia type 3 and type 1 and Huntington's disease Financing led by Ackermans & van Haaren along with Droia Ventures, EQT Life Sciences and Kurma Partners with participation from Polaris...Vico Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659 in Huntington's Disease and Spinocerebellar Ataxia Types 1 and 3
VO659 is the only clinical-stage candidate targeting the CAG repeat expansion that causes these diseases VO659 was designed to preferentially reduce mutant HTT and spare wild-type HTT Phase 1/2a basket trial design and preclinical VO659 data to be presented at CHDI Foundation's 18th...Vico Therapeutics Appoints Scott Schobel, MD as Chief Medical Officer
Dr. Schobel joins Vico from Roche where he was clinical science leader for the tominersen development program for Huntington's disease LEIDEN, Netherlands, Oct. 3, 2022 /PRNewswire/ -- Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding VICO Therapeutics
Sign Up For FreeTo access detailed company insights
Vico Therapeutics is a neurology genetic medicine company that pioneers RNA-based therapies targeting the root causes of rare genetic neurological diseases, specifically focusing on polyglutamine disorders like Huntington's disease and spinocerebellar ataxias. Their lead candidate, VO659, employs an innovative allele-preferential approach to reduce... Read More
